Nikolai Khaltaev GARD Meeting ERS Congress 3 September, Munich

Slides:



Advertisements
Similar presentations
William C. Cushman, MD, FACP, FAHA Veterans Affairs Medical Center, Memphis, TN For The ACCORD Study Group.
Advertisements

Rethinking Lower Blood Pressure Goals for Diabetic Patients with Coronary Artery Disease – Findings from the INternational VErapamil SR – Trandolapril.
April 12, 2011Nielsen - SLA PHT Division Spring Meeting 1 SLA Pharma & Health Technology Spring Meeting 2011 The P-D-R Blueprint for an Ideal Corporate.
For(int i = 1; i
THE AFTERMATH OF THE ASTRA ZENECA CASE. 2 ASTRA ZENECA CASE IS A PART OF A WIDER PHARMA SECTOR LANDSCAPE The landscape of competition law enforcement.
Fibrillation Auriculaire: Thérapies en Amont Fibrillation Auriculaire: Thérapies en Amont Gerald V. Naccarelli M.D. Research support: Boston-Scientific,
The AMDA Exhibit & Marketing Prospectus will be available in June! Why Invest in AMDA? Quick Facts 85% of Medical Directors work part-time and 91% also.
PubMed was searched for randomized clinical trials published between 2007 and 2012 in the New England Journal of Medicine (NEJM) Trials were included if.
2014. Diamond Members  Alexion  Bristol Myers Squibb  Cardinal Health  Eisai, Inc.  Foundation Medicine  Genomic Health  McKesson  MedImmune.
Neoforma Pharmaceutical Contract Management Solution IdealECP™
Pharmaceutical Industry and Boehringer Ingelheim Paul Fonteyne Executive Vice President Head of Marketing & Sales, Prescription Medicines Pharmaceutical.
HUG work team ‚membership / build community‘ Brussels, 20th June 2005  statements from HUG members  general remarks regarding expansion  prioritization.
U.S. Diabetes Therapies and Complications Markets “The growing demand and the introduction of technologically advanced products is likely to transform.
Child Health Advantage Program Overview Chinese American IPA October 28 th, 2014.
A Framework for Rational Decision Making. 2 Health Companies Alcon Abbott Laboratories Fund Baxter BD Boehringer Ingelheim Cares Foundation Bristol-Myers.
How Much AF is Too Much AF? Do I Initiate Anticoagulation Based on AF Detected on Device Monitoring? Kenneth W. Mahaffey, MD, FACC Professor of Medicine,
Chronic Diseases and Health Promotion – Global Alliance against Chronic Respiratory Diseases -
INTERNAL ASSESSMENT FINANCE/ACCOUNTING THREE DECISION AREAS; INVESTMENT DECISION- WHAT ASSETS TO BUY FINANCING DECISION- WHAT IS THE BEST CAPITAL STRUCTURE.
U.S. Pharmacogenomics Markets Key Alliances and Pro-Active Networking Efforts Essential for Success "Investors and established companies should begin scouting.
PRISM Forum Business Discussion Johnson & Johnson La Jolla, CA – USA 21 st October 2010.
U.S. Asthma Therapies Markets Growing Penetration of Combination Drugs Spur Growth “The tremendous success of bronchodilator/-corticosteroid combination.
CHARISMA: The “CAPRIE-like” Cohort Deepak L. Bhatt MD, FACC, FSCAI, FESC, FACP Associate Director, Cleveland Clinic Cardiovascular Coordinating Center.
U.S. Pain Management Pharmaceutical Markets The Emergence Of New Therapeutic Categories Drives Growth “ The Pain Management Pharmaceuticals Markets scenario.
© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Emerging Pulmonary Drug Delivery Technologies Markets Technological Innovation to Drastically.
Hajar Sabuur Johnson & Johnson Worldwide Information Security June 16, 2005
QUANTOS – Quantum Leap in the Lab Amrit Duhela UK Powder Dosing Specialist.
© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Anticoagulant and Antiplatelet Therapies Markets New Generation Therapies Signify Market Growth.
U.S. Asthma Therapeutics Market New Product Classes Offer Significant Growth Opportunities “The emergence of leukotriene modifiers and combination therapies.
© Copyright 2002 Frost & Sullivan. All Rights Reserved. U.S. Lipid Regulators Markets New Clinical Trials Should Spark Interest in Lipid Regulators "A.
Report from GARD secretariat Nikolai Khaltaev, MD, PhD March 2006, GARD General Meeting, Beijing, China.
Chronic Diseases and Health Promotion – Global Alliance against Chronic Respiratory Diseases -
Global Heparin Market WEBSITE Single User License: US$ 2500 No of Pages: 73 Corporate User License: US$ 4000.
United States Parkinson's Disease Drug Market 2016:Industry Trends and Analysis
Global Respiratory Drugs Market WEBSITE Single User License: US$ 2500 No of Pages: 120 Corporate User License: US$
Browse more Reports on Cancer therapeutics at therapeuticshttp://
© Copyright 2004 Frost & Sullivan. All Rights Reserved. The European Active Pharmaceutical Ingredients Market Study and Outsourcing Trends Healthcare Group.
Pembrolizumab Market Consumption, Revenue, Price and Gross Margin 2021 Forecast Published: Nov 2016 Single User License: US$ 2900 Corporate User License:
Retinoblastoma-Pipeline Review, H Phone No.: +1 (214) id:
Global Unfractionated Heparin Sales Market Report 2017.
Global Imitrex Sales Market Report  The Report added on Imitrex Sales Market by DecisionDatabases.com to its huge database. This research study.
Global Active Pharmaceutical Ingredients Market 2017 Analysis, Segmentation, Competitors Analysis, Trends and Forecast by 2022 Phone No.: +1 (214)
Global Orphan Drug Market 2017 Analysis, Segmentation, Competitors Analysis, Trends and Forecast by 2022 Phone No.: +1 (214) id:
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
Global and Europe Antibiotics Market - Analysis and Outlook to 2022
Mitchell W. Krucoff, MD, FACC
S M&A Expertise in Healthcare and Life Sciences: Top 10 Pharmaceutical Deals All-Time &C has played a leading role in the consolidation.
Classification of chronic obstructive pulmonary disease (COPD) severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD):
Global Vaccines Market to witness growth of 9% CAGR from 2017 to 2024
Automotive Electronics Market Size
Acyclovir Cream Buy Online
Continental Travel DMC
Pharmacovigilance Market to grow at 10% CAGR from 2017 to 2024
Over the Counter (OTC) Drugs & Dietary Supplements Market Global Opportunity Analysis and Industry Forecast,
CIS /26/16 Rueben Julfaian Merck & Co.
Effects of Combination Lipid Therapy on Cardiovascular Events in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk in Diabetes (ACCORD)
דיני חברות ד"ר ויקטור ח. בוגנים
Primary data collection versus use of retrospective claims data: methodology lessons learned from a linked database study in chronic obstructive pulmonary.
Balancing Regulation Against Access to Innovative Pharmaceuticals
Antibacterial drug discovery: is it all downhill from here?
with regard to our presentation.
Matters requiring disclosure of COI
Strategic Planning Timeline Overview
Companies and structure FERi ag
Active Pharmaceutical Ingredients Market Research Report – Forecast to 2023 Global Industry Survey, Growth, Competitive Landscape and Forecasts to 2023.
Research and Publications
with regard to our presentation.
Research and Publications
Global Immunosuppressive Drug Market Research an Forecast
Active Pharmaceutical Ingredients Market Industry Insights, Growth, Segmentation and Forecasts to 2023 PREPARED BY Market Research Future (Part of Wantstats.
Causes and predictors of short, intermediate and long-term mortality in patients with coronary artery disease M. Zeitouni, N. Procopi, O. Barthélémy, Q.
Presentation transcript:

Nikolai Khaltaev GARD Meeting ERS Congress 3 September, Munich Mid Term Financial Report January – July 2006 Nikolai Khaltaev GARD Meeting ERS Congress 3 September, Munich

Overview GARD Contributions

Companies accepted by WHO as GARD Observers Altana Pharma Astra Zeneca Boehringer-Ingelheim Int. GmbH Chiesi Farmaceutici S.p.A. GlaxoSmithKline Merck & Co., Inc. Mitsubishi Pharma Corporation Novartis Pharma AG Pfizer Inc. Sanofi-Aventis Schering Plough Corporation Stallergens SA UCB Farchim SA

Overview GARD Expenses

Detailed GARD Expenses obligated from GARD Participants

Detailed GARD Expenses obligated from GARD Observers

Remaining Balance Total Allotted Contributions 465,651 Total Obligated and Earmarked Expenses 419,016 Remaining Balance 46,635